Neil R Poulter Selected Research

LDL Cholesterol

10/2023	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
8/2023	Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study.
1/2020	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
1/2015	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Neil R Poulter Research Topics

Disease

110	Hypertension (High Blood Pressure) 02/2024 - 06/2004
29	Stroke (Strokes) 01/2024 - 04/2003
26	Type 2 Diabetes Mellitus (MODY) 01/2020 - 05/2005
18	Cardiovascular Diseases (Cardiovascular Disease) 10/2023 - 04/2003
17	Myocardial Infarction 01/2022 - 01/2005
15	Coronary Disease (Coronary Heart Disease) 03/2014 - 04/2003
9	Obesity 01/2023 - 04/2019
8	Overweight 05/2021 - 04/2019
7	Heart Failure 01/2022 - 01/2005
6	Diabetes Mellitus 05/2021 - 07/2008
5	Vascular Diseases (Vascular Disease) 01/2022 - 10/2012
5	Chronic Renal Insufficiency 01/2020 - 12/2012
4	COVID-19 02/2024 - 01/2021
4	Hypoglycemia (Reactive Hypoglycemia) 01/2020 - 01/2017
3	Essential Hypertension 02/2024 - 04/2007
3	Atherosclerosis 10/2023 - 01/2021
2	Atrial Fibrillation 01/2024 - 09/2009
2	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 01/2017
2	Body Weight (Weight, Body) 01/2020 - 01/2015
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 04/2019 - 01/2018
2	Albuminuria 01/2019 - 08/2009
2	Pancreatitis 01/2018 - 01/2016
2	Neoplasms (Cancer) 09/2017 - 09/2013
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2017 - 08/2009
2	Coronary Artery Disease (Coronary Atherosclerosis) 09/2009 - 09/2005
1	Isolated Systolic Hypertension 10/2023
1	Venous Thromboembolism 01/2022
1	Noncommunicable Diseases 05/2021
1	Abdominal Obesity 04/2019
1	Kidney Diseases (Kidney Disease) 12/2018
1	Unstable Angina 01/2018
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018
1	medullary Thyroid cancer 01/2018
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2017
1	Abdominal Aortic Aneurysm 11/2016
1	Infections 10/2011
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 10/2011
1	Dizziness (Lightheadedness) 07/2008
1	Edema (Dropsy) 07/2008
1	Fatigue 07/2008
1	Headache (Headaches) 07/2008

Drug/Important Bio-Agent (IBA)

96	Antihypertensive Agents (Antihypertensives)IBA 02/2024 - 06/2004
18	SolutionsIBA 09/2022 - 04/2019
13	LipidsIBA 05/2021 - 04/2003
12	Amlodipine (Norvasc)FDA LinkGeneric 02/2024 - 09/2005
12	Liraglutide FDA Link 01/2020 - 11/2013
12	Atorvastatin (Lipitor)FDA Link 01/2016 - 04/2003
9	Atenolol (Tenormin)FDA LinkGeneric 01/2024 - 09/2005
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2022 - 09/2005
7	Insulin (Novolin)FDA Link 01/2020 - 11/2013
7	CholesterolIBA 10/2012 - 04/2003
6	Insulin Glargine (Lantus)FDA Link 01/2020 - 09/2016
6	insulin degludecIBA 01/2020 - 09/2016
5	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2022 - 01/2005
5	omega-Chloroacetophenone (Mace)IBA 01/2020 - 01/2017
5	Glucagon-Like Peptide-1 ReceptorIBA 01/2020 - 01/2016
4	LDL CholesterolIBA 10/2023 - 01/2015
4	Gliclazide (Diamicron)IBA 01/2022 - 10/2012
4	perindopril drug combination indapamideIBA 01/2022 - 10/2012
4	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 10/2011
4	HDL CholesterolIBA 01/2019 - 04/2003
3	oxidized low density lipoproteinIBA 10/2023 - 01/2021
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 09/2022 - 10/2011
3	Perindopril FDA LinkGeneric 01/2022 - 09/2005
3	CreatinineIBA 12/2020 - 01/2017
3	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2020 - 01/2016
3	Glucagon-Like Peptide 1 (GLP 1)IBA 12/2018 - 01/2016
3	Pravastatin (Pravachol)FDA LinkGeneric 01/2017 - 01/2016
2	SaltsIBA 01/2023 - 11/2016
2	Hemoglobins (Hemoglobin)IBA 01/2022 - 10/2018
2	Angiotensin Receptor AntagonistsIBA 01/2022 - 01/2021
2	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 06/2019 - 05/2010
2	Drug CombinationsIBA 08/2015 - 09/2005
2	DiureticsIBA 05/2010 - 09/2005
1	Blood Glucose (Blood Sugar)IBA 01/2022
1	Indapamide FDA LinkGeneric 01/2022
1	4- (benzyloxy)- 2,6- diamino- 5- nitropyrimidineIBA 05/2021
1	Cystatin CIBA 12/2020
1	MercuryIBA 08/2020
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2020
1	AlbuminsIBA 01/2020
1	Exenatide (Byetta)FDA Link 10/2018
1	Biomarkers (Surrogate Marker)IBA 11/2016
1	Coenzyme A (CoA)IBA 01/2015
1	Oxidoreductases (Dehydrogenase)IBA 01/2015
1	Brain Natriuretic Peptide (Natrecor)FDA Link 03/2014
1	pro-brain natriuretic peptide (1-76)IBA 03/2014
1	Hypoglycemic Agents (Hypoglycemics)IBA 11/2013
1	Glucagon-Like Peptide ReceptorsIBA 11/2013
1	ReninIBA 12/2012
1	perindopril drug combination amlodipineIBA 12/2011
1	A 17 (A-17)IBA 03/2010
1	ORALIT (ORS)IBA 08/2009
1	Doxazosin (Cardura)FDA LinkGeneric 07/2008

Therapy/Procedure

18	Therapeutics 09/2022 - 08/2006
2	Secondary Prevention 05/2021 - 01/2017
1	Critical Care (Surgical Intensive Care) 01/2022
1	Artificial Respiration (Mechanical Ventilation) 01/2022
1	Sphygmomanometers 08/2020
1	Diet Therapy (Therapy, Diet) 01/2018